Here are the The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
The sodium/glucose cotransporter 2 inhibitor empagliflozin metformin, the sodium/glucose cotransporter 2 inhibitors, the sodium/glucose cotransporter 2 inhibitor empagliflozin action, the sodium/glucose cotransporter 2 inhibitor empagliflozin side, what powers the sodium glucose symporter.
The sodium/glucose cotransporter 2 inhibitor Empagliflozin inhibits long QT 3 late sodium currents in a mutation specific manner
Background: Sodium/glucose cotransporter 2 inhibitors (SGLT2is) like empagliflozin have demonstrated cardioprotective effects in patients with or without diabetes. SGLT2is have been shown to selectively inhibit the late component of cardiac sodium current (late INa). Induction of late INa is the primary mechanism in the pathophysiology of congenital long QT syndrome type 3 (LQT3) gain-of-function mutations in the SCN5A gene encoding Nav1.5. We investigated empagliflozin's effect on late INa in thirteen known LQT3 mutations located in distinct regions of the channel.
Methods: The whole-cell patch-clamp technique was used to investigate the effect of empagliflozin on late INa in recombinantly expressed Nav1.5 channels containing different LQT3 mutations. Molecular modeling of human Nav1.5 and simulations in a mathematical model of human ventricular myocytes were used to extrapolate our experimental results to excitation-contractio n coupling.
Results: Empagliflozin selectively inhibited late INa in LQT3 mutations in the inactivation gate region of Nav1.5, without affecting peak current or channel kinetics. In contrast, empagliflozin inhibited both peak and late INa in mutations in the S4 voltage-sensing regions, altered channel gating, and slowed recovery from inactivation. Empagliflozin had no effect on late/peak INa or channel kinetics in channels with mutations in the putative empagliflozin binding region. Simulation results predict that empagliflozin may have a desirable therapeutic effect in LQT3 mutations in the inactivation gate region. Conclusions: Empagliflozin selectively inhibits late INa, without affecting channel kinetics, in LQT3 mutations in the inactivation gate region. Empagliflozin may thus be a promising precision medicine approach for patients with specific LQT3 mutations. © 2024
Authors : Lunsonga L.C.; Fatehi M.; Long W.; Barr A.J.; Gruber B.; Chattopadhyay A.; Barakat K.; Edwards A.G.; Light P.E.
Source : Academic Press
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1016/j.yjmcc.2024.11.014 |
| ISSN | 00222828 |
| Volume | 198 |
You can download the article here
If You have any problem, contact us here